OnKure Therapeutics reported Q1 2026 results highlighting the nomination of two next-generation PI3Kα pan-mutant selective inhibitors, OKI-355 for vascular anomalies and OKI-345 for breast cancer. The company secured $150 million in private placement funding to support clinical development planned for 2027, with $192 million cash on hand expected to fund operations through 2029. OnKure is focusing on these inhibitors to provide targeted therapies with fewer toxicities and plans to submit IND applications to the FDA in the first half of 2027. The company also announced it will not independently pursue further development of OKI-219, another PI3Kα inhibitor, shifting focus to the new candidates.
CBAK Energy Technology showcased its innovative lithium-ion and sodium-ion cylindrical batteries designed for Southeast Asia's electric two- and three-wheelers at Autotech & Accessories 2026. Their batteries feature long life, high reliability, and s...
WeRide and Renault Group continue their partnership by operating the autonomous Robobus shuttle service at the Roland-Garros tennis tournament for the third consecutive year. The service runs a 2.8 km route connecting key points around the stadium, o...
Municipality Finance Plc has issued a $1 billion benchmark bond under its Medium Term Note (MTN) programme, with a fixed interest rate of 4.25% per annum and maturity set for May 27, 2031. This bond is part of MuniFin's EUR 50 billion debt issuance p...
Eli Lilly reported positive Phase 1b results for VERVE-102, a gene therapy that permanently silences the PCSK9 gene to reduce LDL cholesterol by up to 62%. The therapy showed sustained effects for up to 18 months and was well-tolerated with no seriou...
SpaceX's upcoming IPO may cause forced ETF buying of $22-$27 billion as Nasdaq changes rules to fast-track the company's index inclusion. The Nasdaq 100 now allows new companies to join within 15 days if their market cap ranks in the top 40, removing...
